Summary. Understanding the pathogenesis of osteoarthritis (OA) provides invaluable information in the search of therapeutic targets for the development of disease-modifying OA drugs. Emerging results from investigations demonstrate that the pericellular matrix of chondrocytes plays important roles in protecting articular cartilages from being degraded. Thus, maintaining the structural integrity of the pericellular matrix may be an effective approach to prevent the development of osteoarthritic joints. In this review article, we discuss the consequences of lacking one or more components of the pericellular matrix, and biological effects of the destruction of the pericellular matrix in the development of OA. We believe that more attention should be directed towards the pericellular matrix for the identification of novel biomarkers and therapeutic targets for the prevention and treatment of OA.

Key words: Osteoarthritis, Articular cartilage, Chondron, Pericellular matrix, Animal model

Introduction

Osteoarthritis (OA) is considered a whole joint disease that involves articular cartilage, subchondral bone, synovial membrane, menisci and ligaments (Loeser et al., 2012). It has been suggested that OA is caused by genetic, biochemical and biomechanical factors. One of the pathological hallmarks in OA is the destruction of articular cartilage. The main cellular events underlying cartilage destruction are type II collagen degradation and loss of proteoglycans, resulting from an imbalance between anabolic and catabolic activities in joints. The immediate pericellular environment of chondrocytes appears to have a critical role in regulating chondrocyte activities. Chondrocytes together with a pericellular environment (matrix) are referred to as chondrons. Much effort has been made to understand the biological and biomechanical functions of the pericellular matrix (PCM). In this review article, we discuss important roles of the PCM in maintaining the homeostasis of articular cartilages and in the development of OA.

Anatomical structure of chondrons

Articular cartilage consists of chondrocytes and an expansive extracellular matrix (ECM), which includes pericellular, territorial and interterritorial matrices. The concept of a chondron has been introduced to
specifically refer to the chondrocyte together with its surrounding. It was originally suggested that chondrons were the primary structural and functional units of articular cartilage (Poole et al., 1988, 1990). Later, a research group completed additional experiments to physically isolate chondrons from cartilage. Results from their study show that chondrons were the primary functional and metabolic unit of articular cartilage (Hunziker et al., 1997; Poole, 1997).

The PCM contains components such as laminin, fibronectin, biglycan, decorin, fibromodulin, matrilins 1 and 3, cartilage oligo matrix protein (COMP), and type VI and IX collagens (Roughley, 2001; Guilak et al., 2006). The pericellular capsule is mostly composed of collagens type VI and IX, and proteoglycans (Li and Xu, 2015). The PCM separates chondrocytes from the adjacent interterritorial or territorial matrices. One of the characteristics in the pericellular matrix is that it lacks type II collagen fibrils in the matrix. Thus, under normal conditions, type II collagen fibrils are not exposed to chondrocytes. It is conceivable that the disruption or disappearance of the PCM would enhance the exposure of chondrocytes to type II collagen fibrils. This, in turn, should elicit the interaction of collagen type II fibrils with cell surface receptors, which leads to the down- or up-regulation of intracellular signaling pathways and the alteration of chondrocyte metabolism (Xu et al., 2011). In fact, Poole’s group demonstrates that the structure of the pericellular matrix of chondrocytes is disrupted in human OA cartilage (Poole et al., 1991).

Deletions of the pericellular components leading to early onset osteoarthritis

Results from human and mouse genetic studies indicate the significant roles the components in the PCM play in protecting articular cartilage against the development of OA (Schminke et al., 2016). For example, several clinical studies report that mutations in the genes that encode type IX collagen (COL9A1, COL9A2 and COL9A3) cause multiple epiphyseal dysplasia (MED), which is characterized by mild short stature and early onset OA (Bonnemann et al., 2000; Mustafa et al., 2000; Czarny-Ratajczak et al., 2001; Jackson et al., 2010). Results from mouse genetic studies demonstrate that the deletion of Col9a1 results in age-dependent OA-like changes in knee and temporomandibular joints (TMJ), characterized by an increase in the degradation of collagen type II and proteoglycans and an increased expression of matrix metalloproteinase 13 (Mmp-13) and discoidin domain receptor 2 (Ddr2) (Hu et al., 2006). Additionally, changes in cartilage mechanical properties have been observed in the femoral and tibial plateaus of Col9a1-/- mice. This suggests that the lack of collagen type IX results in early onset OA.

Collagen type VI, primarily in the PCM, has been reported to play a protective role for chondrocytes by maintaining the pericellular microenvironment in OA (Horikawa et al., 2004; Owida et al., 2017). Loss of pericellular type VI collagen has been observed to be associated with abnormal human chondrocytes in non-degenerated cartilage, demonstrating that the lack of collagen type VI could lead to cartilage degeneration (Murray et al., 2010). A study reports that the genetic deletion of collagen type VI in mice alters the mechanical environment surrounding chondrocytes during joint loading, which eventually leads to the development of OA (Alexopoulos et al., 2009; Zelenski et al., 2015).

In humans, mutations in matrilin-3 cause MED and Spondyloepimetaphyseal Dysplasia (SEMD) (Chapman et al., 2001; Borochowitz et al., 2004; Otten et al., 2010). Matrilin-3-deficient mice reveal early onset OA-like changes in knee joints, including premature hypertrophic chondrocytes, chondrocyte clustering, fibrillation and osteophyte formation (Ko et al., 2004; van der Weyden et al., 2006). In matrilin-3 knockout mice, the level of collagen type II and aggrecan are reduced compared to that in wild-type littermates. This indicates that matrilin-3 plays an important role in maintaining the structural integrity of articular cartilage. It has also been reported that the expression level of matrilin-3 is increased in OA and is correlated with disease severity. Matrilin-3 induces osteoarthritis-associated markers in chondrocytes in a concentration-dependent manner (Muttigi et al., 2016). The function of matrilin-3 shifts from an anabolic to a catabolic effect in articular cartilage. At the concentration of <10 µg/mL, soluble matrilin-3 treatment induces the expression of collagen type II and inhibits the expression of MMP-13. On the other hand, at the concentration of ≥20 µg/mL, matrilin-3 increases the expression of MMP13 (Vincourt et al., 2012). A very recent study reports that the genetic deletion of matrilin-1, another component in the PCM, results in severe articular cartilage lesions, induced by destabilization of medial meniscus (DMM), in mouse knee joints (Chen et al., 2016).

Mutations in cartilage oligomeric matrix protein (COMP) are associated with MED. In a case-control study, the serum level of COMP is significantly higher in OA patients than in control individuals (Verma and Dalal, 2013). In an animal model study using rabbits, it has been shown that the elevated levels of COMP and MMP-3 in serum and joint fluid are correlated with OA severity (Chu et al., 2015). Similarly, mutations in Comp result in chondrodysplasia in mice (Pirog-Garcia et al., 2007; Suleman et al., 2012).

The genetic deletion of decorin, biglycan and fibromodulin are also associated with early onset OA in TMJ of mice (Bock et al., 2001; Alexopoulos et al., 2005b; Wadhwa et al., 2005). The deficiency of biglycan and fibromodulin increases the apoptosis of chondrocytes. This, in turn, leads to the premature erosion and degradation of condylar cartilage in TMJ. The data underscores the important role of biglycan and fibromodulin in the maintenance of condylar cartilage integrity of the TMJ (Wadhwa et al., 2005; Embree et al., 2010). However, a very recent study shows that
decorin-deficient mice have significantly less damage of knee joints than their wild-type littermates after the mice were exercised extensively. Results also show the stiffness of articular cartilages is increased in decorin-deficient mice. Thus, the investigators in this study suggest that the protective effect of decorin deficiency may be due to the increased stiffness (Gronau et al., 2000; Muhammad et al., 2012; Zelenski et al., 2015). These findings suggest that cell-matrix interactions may play an important role in the response of chondrocytes to mechanical compression.

The distinct biomechanical properties of the PCM have been measured by techniques such as micropipette aspiration, in situ imaging, computational modeling, and atomic force microscopy (AFM). Micropipette aspiration studies have provided direct quantitative measurements of PCM elastic and biphasic properties and have demonstrated the mechanical properties of PCM (Alexopoulos et al., 2003, 2005b). These studies suggest that the presence of PCM significantly affects the micromechanical environment of the chondrocyte as a zone-dependent manner (Alexopoulos et al., 2005a). In situ imaging studies have investigated the relative deformations of chondrocytes, PCM and ECM (Choi et al., 2007). These studies indicate that PCM may regulate either amplification or shielding of forces, depending on chondrocyte position within tissue. By combining imaging and application of the computational model, the mechanical properties of PCM can be estimated during mechanical loading (Michalek and Iatridis, 2007; Kim et al., 2010). Atomic force microscopy (AFM)-based microindentation has been applied to avoid artificial alterations caused by physical extraction of PCM. By use of AFM-based stiffness mapping, PCM elastic moduli are tested in human cartilage (Darling et al., 2010). AFM with fluorescence microscopy has also been utilized to analyze the biomechanical properties of PCM and the correlation among structural features and biochemical composition (Wilusz et al., 2012b, 2013).

Loss of PCM mechanical properties has been characterized at the macroscale, microscale, and nanoscale in both human OA tissue and experimental animal models. Micropipette aspiration studies reveal that chondrons from human OA cartilage exhibit a 30–40% decrease in Young’s moduli, compared with chondrons from healthy tissue (Alexopoulos et al., 2003). A study of elastic mapping indicates a significant loss of mechanical properties of PCM in OA cartilage. The PCM elastic moduli in OA cartilage are reduced by 30% as compared to that in normal cartilage (Wilusz et al., 2012b). This study also demonstrates that in OA cartilage, there is a shallower gradient in the change of modulus outward from PCM to ECM, as compared to the sharper transition observed in normal cartilage.

The biomechanical properties of PCM are influenced by specific PCM components. For example, PCM plays the role of a mechanical transducer during the interaction of type VI collagen with cell surface integrins or hyaluronan (Zelenski et al., 2015). Results from a study of isolated chondrons show that PCM moduli were
reduced by one-third in heterozygous Col6a1 +/- mice and by two-thirds in Col6a1 -/- mice (Alexopoulos et al., 2009). Knockout of type VI collagen was also shown to increase the extent of cell swelling and osmotically induced TRPV4 (transient receptor potential vanilloid channel 4) signaling in an age-dependent manner, and can accelerate the progression of OA (Zelenski et al., 2015). Another molecule that contributes significantly to PCM properties is perlecan. Perlecan and collagen type VI co-localized regions have lower modulus regions than type VI collagen alone area (Wilusz et al., 2012a). Studies also reported that perlecan may play a role in mechanotransduction to release FGF-2 by mechanical loading (Vincent et al., 2007; Wilusz et al., 2014).

In summary, the aforementioned results from the mechanical studies of PCM demonstrate that the matrix may play a protective role to chondrocytes responding to mechanical stresses. Also, disease-related PCM structure and biomechanical properties may affect the way chondrocytes sense and respond to normal mechanical loading, contributing to further matrix degradation and disease progression.

Pericellular matrix in maintaining homeostasis of chondrocyte metabolism

The disappearance of PCM of chondrocytes exposes chondrocytes to molecules in territorial and interterritorial matrices, particularly collagen type II. Thus, PCM prevents collagen type II from binding to its cognate receptor, discoidin domain receptor 2 (DDR2), in articular cartilages. DDR2 is a cell surface receptor tyrosine kinase (RTK) and is activated by binding of the receptor with collagen type II (Shrivastava et al., 1997; Vogel et al., 1997; Xu et al., 2011). It is conceivable that the activation of DDR2 transduces signaling to turn on/off genes in chondrocytes. This, in turn, changes chondrocyte activities (Goldring, 2012). In fact, in the last ten years, data from our investigations and other studies demonstrate that the activation of DDR2 induces the expression of MMP-13, one of the major extracellular matrix degrading enzymes (Xu et al., 2005, 2007; Vonk et al., 2011). The end result is OA.

DDR2 was originally cloned in 1993 (Di Marco et al., 1993; Karn et al., 1993, Zerlin et al., 1993). Two independent research groups have identified specific amino acids on DDR2 and collagen type II, which are critical for the interaction of the two molecules. A change in any of these amino acids will dramatically affect the affinity of DDR2 with collagen type II (Leitinger et al., 2004, Ichikawa et al., 2007; Konitsiotis et al., 2008). To understand the signaling mechanism responsible for the induction of MMP-13 by the activation of DDR2, a series of experiments were performed (Xu et al., 2005, 2007, 2009; Sunk et al., 2007; Goldring, 2012; Schminke et al., 2014). Results from these experiments showed that the expression of MMP-13 was elevated in chondrocytes cultured on type II collagen. Surprisingly, the expression of DDR2 was also found to be increased in the chondrocytes. This indicated that chondrocytes exposed to native collagen type II were induced the expression of MMP-13 and the DDR2 receptor itself. In addition, when chondrocytes were cultured on the denatured type II collagen, gelatin, the expression of MMP-13 and DDR2 were not induced, suggesting that the chondrocytes responded in a specific manner to triple-helical type II collagen. Moreover, the overexpression of full-length DDR2 cDNA resulted in increased expression of MMP-13, whereas the overexpression of a truncated DDR2 cDNA (lacking the

Pericellular matrix in the development of osteoarthritis

Fig. 1. Down-stream signaling pathways of DDR2 in chondrocyte. The interaction of DDR2 with collagen type II activates signaling pathways including ERK, p38, IL-1β, IL-8 and NF-κB, which leads to the synthesis and release of MMP-13. DDR2 up-regulates the expression of the receptor itself by the protein kinase C pathway.
protein tyrosine kinase) inhibited the increased expression of MMP-13. In addition, DDR2 lacking type II collagen-binding domain (discoidin domain) of the receptor had no effect on the expression of MMP-13 and the receptor itself. These results indicate that increased expression of MMP-13 in chondrocytes requires the interaction of DDR2 with type II collagen. The data also show that Ras/Raf/MEK/ERK and p38 signaling pathways were involved in the induction of MMP-13 in chondrocytes by collagen type II-DDR2 interaction. In addition, another research group reports that DDR2 increases the expression of the receptor itself by a protein kinase C-dependent pathway (Vonk et al., 2011), see Figure 1. Furthermore, transgenic mice were generated that conditionally overexpressed Ddr2 in mature articular cartilage on mouse knee joints. However, there was no induction of Mmp-13 in the cartilage (Xu et al., 2011). The result suggests that conditionally overexpressed Ddr2 in transgenic mice is not activated since the receptor is still separated from collagen type II by PCM. This observation is in agreement with the result from another independent investigation, which demonstrates that Mmp-13 is not induced in chondron cultured on collagen type II coated plates (Vonk et al., 2011).

On the basis of the findings from in vitro experiments, studies were carried out in vivo to understand the potential roles of DDR2 in the development of OA. The expression of DDR2 was examined in human osteoarthritic tissues and mouse models of OA. It was found that DDR2 protein was barely detectable in normal articular cartilage. However, the expression of DDR2 was increased in human osteoarthritic tissues and mouse models of OA (Lam et al., 2007; Sunk et al., 2007; Xu et al., 2007). Moreover, DDR2 was co-localized with the increased activity and expression of MMP-13 in degenerative articular cartilage. More importantly, by utilizing the conditional knockout technique, we were able to delete Ddr2 prior to, and after the onset of, articular cartilage degeneration induced by the destabilization of the medial meniscus (DMM). Our results indicated that articular cartilage was protected under both conditions against the development of OA (Manning et al., 2016). We also conditionally removed Ddr2 from a genetic form of the mouse model of OA, collagen type XI-haploinsufficient mice (Col11a1+/−). We found similar results to what was observed in the DMM model (unpublished data). Moreover the result from another independent research group indicates that the expression of Ddr2 is increased in the articular cartilage of knee joints of a spontaneous mouse model of OA (Holt et al., 2012). A study reports that DR1 may also play a role in the development of OA in TMJ (Schminke et al., 2014).

In summary, the degradation of PCM enhances the exposure of DDR2 to collagen type II and elicits the interaction of the receptor with collagen type II. This, in turn, activates DDR2 and its down-stream signaling pathways, resulting in the induction of MMP-13 in chondrocytes. MMP-13 degrades collagen type II and proteoglycans, which eventually leads to OA.

Conclusion

OA is the most common form of arthritic disorder. However, there are, currently, no effective drugs to retard the osteoarthritic process once it has initiated. We believe that pericellular matrix is potentially one of the targets for the development of disease-modifying OA drugs. For example, efforts should be made to identify an enzyme(s) responsible for the degradation of pericellular matrix. Biological reagents that inhibit the activity of the enzymes may be developed as drugs to treat OA.

It is worth mentioning that numerous independent research groups, including our group, have reported that a serine protease, high temperature requirement A1 (HTRA1) is highly expressed in human OA cartilage and in mouse models of OA (Hu et al., 1998; Clausen et al., 2002; Grau et al., 2006; Wu et al., 2007; Polur et al., 2010). HTRA1 can degrade the pericellular components. This suggests that HTRA1 may contribute to the development of OA through the degradation of the pericellular network. If so, HTRA1 may be a potential therapeutic target for the development of disease-modifying OA drugs. However, we are aware that results from in vivo experiments are needed to demonstrate the causal relationship of the HTRA1 and the development of OA. Another review article has also discussed PCM as a therapeutic target to development DMOADs (Vincent, 2013).

Acknowledgements. This work was supported by grants from the Key Technology Research and Development Programs of Science and Technology Commission Foundation of Sichuan Province (No. 2016SZ0013), and Foundation of Science & Technology Department of Sichuan Province (No. 2016JY0055).

References

human articular cartilage of late-stage osteoarthritis. Osteoarthritis Cartilage 9, 654-663.


Pericellular matrix in the development of osteoarthritis


Pericellular matrix in the development of osteoarthritis


Accepted January 23, 2018